ARTICLE | Clinical News
Boehringer discontinues PDE-9A inhibitor for AD
February 16, 2018 1:11 PM UTC
Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A) inhibitor.
Pooled data from a total of 457 patients with cognitive impairment due to AD from both trials showed that BI 409306 failed to improve cognition from baseline to week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association International Conference in Chicago in July...
BCIQ Company Profiles